Locally advanced unresectable pancreatic ductal adenocarcinoma

What changed: Locally advanced unresectable pancreatic ductal adenocarcinoma

Cancer page →

Every dated change on the records linked to Locally advanced unresectable pancreatic ductal adenocarcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval1Regulatory1Trial result2Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-18This recordLocally advanced unresectable pancreatic ductal adenocarcinoma
Facts on this page last checked
When this page itself was last checked or edited.

Q1 2026 · 1

2026-Q1RegulatoryOptune / Optune Pax (TTFields)
Optune / Optune Pax (TTFields): approval (US)
Optune Pax, locally advanced pancreatic cancer with chemotherapy (PANOVA-3)

2026 · 3

2025 · 2

2019 · 1

2019MilestoneMR-guided adaptive radiotherapy
Ablative MR-guided radiotherapy for locally advanced disease enters trials
A milestone in how this cancer is treated.

2016 · 1

2016MilestoneChemoradiation (chemoradiotherapy, CRT)
LAP07: chemoradiation after induction gemcitabine controls local growth but does not lengthen survival
A milestone in how this cancer is treated.

2011 · 1

2011MilestoneFOLFIRINOX / mFOLFIRINOX
FOLFIRINOX result in metastatic disease is adopted as induction for locally advanced tumours
A milestone in how this cancer is treated.

1981 · 1

1981MilestoneFluorouracil (5-FU)
Gastrointestinal Tumor Study Group: fluorouracil chemoradiation lengthens survival over radiotherapy alone in locally advanced disease
A milestone in how this cancer is treated.